To examine the anti-tumor activity of the SPARC peptides, mice with subcutaneous neuroblastoma xenografts were treated with either FSEN, FSEC, scrambled peptide scFSEN, or PBS 5 days/week for 2 weeks. Here, SPARC is linked to neuroblastoma.